Isomorphic Labs, the London-based artificial intelligence drug discovery company spun out from Alphabet’s DeepMind division, is engaged in preliminary discussions to secure new funding at a valuation floor of $40 billion, according to multiple sources familiar with the matter.
The discussions remain in their early stages, meaning final terms and investor participation have not yet been finalized. However, the reported valuation floor represents a substantial affirmation of investor confidence in the computational biology sector and the commercial applications of advanced machine learning in pharmaceutical development.
Background on Isomorphic Labs
Founded in 2021, Isomorphic Labs represents Alphabet’s effort to commercialize DeepMind’s breakthrough work in protein structure prediction and molecular biology. The company has positioned itself at the intersection of artificial intelligence and drug discovery, leveraging DeepMind’s AlphaFold technology and other computational advances to accelerate the identification and development of new therapeutics.
The startup’s mission centers on using machine learning algorithms to dramatically reduce the time and cost associated with bringing new drugs to market. Rather than pursuing traditional venture capital funding routes alone, Isomorphic Labs has maintained close ties to its Alphabet parent while building an independent operational structure and pursuing external capital partnerships.
Valuation Trajectory and Market Context
A $40 billion valuation would represent a substantial increase from the company’s previous private valuation metrics, reflecting the growing investor appetite for AI-enabled biotech and drug discovery platforms. The valuation milestone also underscores how artificial intelligence applications in life sciences have attracted significant capital attention from institutional investors, hedge funds, and strategic players.
The funding discussions occur against a backdrop of intensifying competition in the computational drug discovery space. Numerous startups and established pharmaceutical companies are racing to develop proprietary AI systems capable of identifying novel drug candidates and predicting their efficacy and safety profiles.
Implications for European Biotech and Fintech
The reported funding activity highlights the continued dominance of UK-based life sciences companies in attracting substantial venture capital and growth-stage funding. London has consolidated its position as a leading hub for AI-driven biotechnology, particularly following regulatory clarity around AI governance and strengthened patent protections for computational innovations.
For the broader European financial market, the discussions around Isomorphic Labs’ valuation underscore investor enthusiasm for companies combining artificial intelligence with healthcare applications. This trend has implications for European venture capital deployment, public market readiness for biotech IPOs, and regulatory frameworks governing AI use in pharmaceutical development.
The preliminary nature of these funding discussions means the final terms, investor composition, and timing remain uncertain. Nevertheless, the reported valuation floor signals continued confidence in the commercial potential of applying machine learning to drug discovery, a sector that could reshape pharmaceutical innovation over the coming decade.